Clinical Trial Update: Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetics and safety pilot study evaluating single-dose oral and intravenous CTAP101 in stage 3–4 chronic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• CTAP101

Snippet

Sponsor: OPKO IP Holdings II, Inc. | Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism | Phase 1 | Status: COMPLETED